Global Health Limited (MEDANTA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Global Health Limited, the operator of the Medanta hospital chain, faces a critical quarter as it balances the aggressive ramp-up of its Noida facility against rising operational costs. Investors will be focused on whether the Noida EBITDA loss continues to narrow toward the targeted H2 FY27 breakeven and how the company manages margin pressure amidst significant clinical talent expansion.

Global Health Limited Q1 Results Date and Time

The board meeting is scheduled for July 30, 2026, to consider the unaudited Q1 FY27 financial results.

The earnings conference call is scheduled for July 31, 2026, at 2:00 PM IST, hosted by JM Financial with participation from Dr. Naresh Trehan, Pankaj Sahni, and Yogesh Gupta.

What to expect from Global Health Limited's Q1 FY27 results

The company is expected to demonstrate revenue growth ahead of the Q1 FY26 base of Rs. 1,051 Cr, supported by the full-quarter contribution of brownfield bed additions and a stable ARPOB trend. The Noida facility's EBITDA loss is likely to narrow from the Rs. 23.6 Cr reported in Q4 FY26, as management targets cash-positive operations within a 3–4 month window from May 2026. While consolidated EBITDA margins will face pressure from the 29.8% YoY growth in employee benefits expense seen in FY26, the ongoing margin expansion in the mature portfolio is expected to partially offset the Noida drag. Investors should monitor the impact of the new CGHS portal transition on receivable cycles, which historically take 6–9 months to realize. Q1 capital expenditure is expected to track toward the annual guidance of Rs. 800–900 Cr, with focus on the Varanasi, Guwahati, and Indore cancer unit projects.

Key Things To Watch

Noida Performance vs Guidance: Tracking the path to H2 FY27 breakeven.

• Quarterly EBITDA loss trajectory relative to Q4 FY26 loss of Rs. 23.6 Cr.
• Occupancy progress from the ~30% level reported as of May 2026 toward the 40–45% breakeven threshold.

Capex Adherence & Project Updates: Monitoring execution of the Rs. 800–900 Cr FY27 capex plan.

• Q1 FY27 spend vs full-year guidance of Rs. 800–900 Cr.
• Status of Varanasi definitive agreement, Guwahati construction, and Indore cancer unit opening.

Risks and headwinds to monitor: Operational and regulatory factors impacting cash flow and margins.

• Potential working capital strain from the new CGHS portal migration launched May 21, 2026.
• Competitive pressure from two new hospitals expected in Gurgaon by Sep–Oct 2026.
• Full-quarter impact of the 550+ clinicians onboarded during FY26 on employee benefit expenses.